Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases

Completed · Early Phase 1

Conditions studied: Autoimmune Disease, Crohn Disease, Inflammatory Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Takayasu Arteritis

In brief

This pilot trial studies how well fluorine F 18 clofarabine positron emission tomography (PET)/computed tomography (CT) works in imaging patients with autoimmune or inflammatory diseases. Fluorine F 18 clofarabine is an imaging agent or tracer which may be taken up by inflammatory tissue in the body. Diagnostic imaging, such as PET/CT scans, can be used to measure the amount of injected tracer that is taken up by inflammatory tissue. PET/CT scan may help to determine how fluorine F 18 clofarabine is distributed throughout the body.

Key facts

Study ID

NCT02925351

Run by

Jonsson Comprehensive Cancer Center

People needed

8

Starts

2016-01-25

Expected to finish

2018-04-30

Last updated by the study team

2020-09-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must be 18 years or older.
• Diagnosed with an autoimmune and inflammatory disorder.

You may not qualify if…

• Women of childbearing age will have to undergo a pregnancy test that will be provided free of charge.
• Patients unable to undergo or comply with PET/CT scanning due to pre-existing medical conditions including claustrophobia.

Where it is running

• UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.